Oral delivery can reduce active availability
Digestive conditions, poor dissolution, and liver metabolism can reduce the amount of unchanged active ingredient entering circulation.
First-pass metabolism occurs when swallowed ingredients travel through the digestive system and liver before reaching general circulation.
During this process, part of an active ingredient may be transformed or broken down before it becomes available to the rest of the body.
Digestive conditions, poor dissolution, and liver metabolism can reduce the amount of unchanged active ingredient entering circulation.
Nano delivery may support improved dispersion and more efficient uptake pathways, helping formulations make more effective use of the active ingredient.
Smaller delivery structures can distribute more evenly throughout compatible liquid and solid formulations.
Reducing particle size increases the available surface area of the active delivery system.
Controlled particle distribution supports consistent active concentration across the finished batch.
Properly designed delivery systems can help reduce settling, separation, and inconsistent product appearance.
Particle size, distribution, stability, potency, and application performance should be evaluated using appropriate technical testing rather than relying only on marketing terminology.
Learn how particle size, ingredient uptake, and digestive processing can influence delivery-system performance.
Speak with our team about particle size, formulation compatibility, nano powders, liquid delivery systems, samples, and technical documentation.